WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
LEXINGTON, Mass., Feb. 01, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/bio/ceoinvestor2016/89132240349.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
